Other Issues:

This Week's Researchers [What is this?]

From Science: AIDS vaccine trial produces disappointment and confusion. On Saturday, 15 February, a team of data analysts from VaxGen checked into a hotel a short drive from their offices in Brisbane, California, using fictitious names. The scientists had come to "unblind" the results of the first-ever, real-world test of an AIDS vaccine, a 4-year study involving 5000 people. By Jon Cohen. [Free full text article] [About AIDScience articles] [See recent AIDScience articles] [dEbates: Submit a response to this article]

AIDScience Perspectives: Cent Gardes vaccine meeting highlights role of antibodies in protection. The 13th Cent Gardes Symposium on HIV and AIDS Vaccines began on an unusual note, turning the spotlight on renewed efforts to make vaccines that induce broadly neutralizing antibodies—following years of discouragement about the prospects for success, and a shift of focus onto vaccines targeting cellular immunity. By Patricia Kahn, from the IAVI Report. [Free full text article] [About AIDScience articles] [See recent AIDScience articles] [dEbates: Submit a response to this article]

Hot News:

VaxGen sticks to its guns. February 27, 2003. VaxGen issued a statement saying that the statistical analyses of the AIDSVAX trials was agreed on in advance with the U.S. FDA, including analyses of various subgroups and racial backgrounds, and the results reported on Monday remain accurate as stated. [Go to full press release] VaxGen announces initial results of its Phase III AIDS vaccine trial. February 24, 2003. Vaxgen, Inc. announced today the initial results from its three-year Phase III trials of AIDSVAX, a recombinant gp120 HIV vaccine. The reduction of HIV infection within the vaccinated population as a whole was not statistically significant. However, there was a statistically significant reduction of HIV infection in vaccinated non-white, non-Hispanic volunteers. More importantly, protection in this subgroup appeared to correlate with a higher level of neutralizing antibodies. [More...] [VaxGen issues statement on clinical trial data analysis] [Media reaction to AIDSVAX Phase III trials results] [Results in graph format] [Results in table format] [Webcast and conference call] (available for five business days)

Env induces virus expression from resting CD4+ T cells isolated from HIV-infected individuals. Production of infectious virus from resting CD4+ T cells isolated from HIV-infected individuals can be induced following exposure of these cells to HIV-1 recombinant (oligomeric gp140) envelope protein and is not associated with markers of classic T cell activation, proliferation, or apoptosis. Journal of Immunology 170(5), 1 March 2003 [Read abstract]

Sexual behavioral interventions and STI treatment did not reduce the incidence of HIV in Uganda. February 25, 2003. Behavioral interventions alone or together with sexually-transmitted infections (STIs) interventions, and routine government health services and community development activities on HIV-1 and other STIs in rural Uganda were not sufficient to reduce the incidence of HIV-1. Lancet 361(9358), 22 February 2003 [Read article] Lancet 361(9358), 22 February 2003 [Read commentary]

Abstracts of the 10th Conference on Retroviruses and Opportunistic Infections. The abstracts of the conference that ran February 10-14, 2003, are now online. [Go to conference site]

ADODB.Connection error '800a0e7a'

Provider cannot be found. It may not be properly installed.

/Issues/Issue045.asp, line 114